Numbers

The Numbers

Centene is a $176B-revenue managed care insurer that ran straight into a wall in 2025: a $6.7B goodwill impairment in Q3, a sharp deterioration in Marketplace and Medicaid medical-cost trend, and a full-year GAAP net loss of -$6.7B. Beneath the wreckage, the underlying engine still generated $5.1B of operating cash flow and $4.3B of free cash flow, while net debt fell to roughly $0.9B. The market is pricing CNC at 0.12x sales and 1.03x book — near 20-year valuation lows — making the entire thesis hinge on whether 2026 earnings can rerate back toward the company's own normalized historical path. The single metric most likely to move the stock from here is medical loss ratio normalization — every 50bps of improvement is worth roughly $0.7B of pretax margin against $194B of premium.

Snapshot

Quality scorecard — is the franchise still intact?

The quality picture is bifurcated: the underlying cash engine and balance sheet have been resilient through two decades of M&A-driven growth, but reported profitability cratered in 2025 from a single non-cash impairment plus an underwriting miss in Marketplace. Altman Z at 2.83 sits firmly in the grey zone — neither distressed nor safe — and matters less than whether 2026 medical loss ratios prove the underwriting was a one-year event.

Revenue & earnings power — 20-year view

Centene compounded revenue at roughly 24% CAGR over 20 years through aggressive acquisition (HealthNet 2016, WellCare 2020, Magellan 2022) and rapid Medicaid/Marketplace expansion. Margins, however, are structurally thin — operating margin has averaged just 2.4% since 2010 even before the 2025 collapse — leaving the business one bad medical cost cycle away from a loss, exactly what 2025 delivered.

Quarterly trajectory — the 2025 break

Revenue actually accelerated in 2025 (top-line up 19% YoY), but operating income inverted: Q3 2025 carried a -$6.95B loss tied to the goodwill impairment, and Q4 stayed negative on Marketplace cost trend. The pattern matters — top-line momentum is intact; the issue is unit economics, not demand.

Cash generation — are the earnings real?

Cash conversion is the most important signal in this name. Across the past decade, CFO has averaged roughly 2.5x net income — a structural feature of the insurance model, where premium reserves and float build CFO ahead of GAAP recognition. The 2024 collapse in CFO (just $0.15B) was timing-driven (Medicaid receivable build) and reversed in 2025 ($5.1B). Despite the GAAP disaster, FY2025 FCF still printed $4.3B, equating to roughly a 21% FCF yield on current market cap.

Capital allocation

Centene pays no dividend. The post-2022 capital allocation pivot is clear: roughly $9B of buybacks across 2022-2025 plus active debt paydown. With shares at multi-year lows, current buyback pace (about $1.5B in 2025) translates to a meaningful 7% of float repurchased annually if sustained.

Balance sheet health

Leverage looks misleadingly negative for 2025 only because EBITDA went negative — net debt itself dropped to $0.9B (from $5.4B in 2024) as the company actively paid down debt and used cash flow generation. Pre-impairment, the balance sheet is the strongest it has been since the WellCare acquisition: $17.9B of cash against $18.8B of debt. This is the single most underappreciated line item — the company has the financial flexibility to absorb another bad year if 2026 underwriting also disappoints.

Valuation — now vs its own 20-year history

This is the single most important visual on the page. CNC's P/Sales has compounded down for nearly a decade, from over 1.5x in 2014 to 0.10x today — the lowest in 20 years and roughly half the 2019-2023 average of 0.33x. P/Book at 1.03x means the market is essentially valuing the franchise at its tangible accounting equity. Forward P/E of 14x is the bridge: it implies analysts model a return toward $3+ EPS in 2026, which would put the multiple meaningfully under the 5-year median P/E of 19x — i.e., the stock is priced cheap if earnings normalize.

Peer comparison

Centene trades at the deepest sales-multiple discount in the group — half of HUM (also struggling) and a third of ELV. The closest comp is HUM, which is also wrestling with cost-trend losses; HUM's forward P/E of 24x against CNC's 14x reflects either greater conviction in HUM's recovery or relative pessimism on Centene's Marketplace exposure. The 0.12x P/Sales is the cheapest in major US managed care.

Fair value & scenario

The base case anchors on management's stated 2026 EPS guide of "above $3" and a 14x multiple, landing close to today's price — the market is pricing exactly the company's own 2026 guide. Upside requires a multiple rerate toward the 5-year median; downside requires guidance to slip again. A simple sales-based cross-check (0.20x P/S × $200B revenue at peer-median = $40B market cap, or roughly $80/share) suggests the historical cross-multiple framework points well above today, but only if the franchise's earnings power reverts.

What to take away

The numbers confirm that Centene's underlying cash engine is still working — $4.3B of FCF and a meaningfully de-levered balance sheet in the same year as a -$6.7B GAAP loss is unusual and durable. They contradict the popular framing of CNC as a low-quality, broken business: cash conversion has averaged 2.5x net income over a decade, and the 2025 disaster was driven primarily by a single non-cash impairment plus a bounded Marketplace underwriting miss. Watch next the Q1 2026 medical loss ratios across Medicaid and Marketplace and management's reaffirmation (or revision) of the "$3+" 2026 EPS guide on April 28, 2026 — that single data point will reset the entire multiple discussion.